All Comments by
- Robert Moir on Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease.
- Helen Cunningham on Miami: Is Human Amyloid Imaging Ready for Clinical Trials?
- Jose Joaquin Merino on Genetics of FTD: New Gene, PGRN Variety, and a Bit of FUS
- Carlo Condello on CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
- Kathleen Zahs on Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.
- Scott Small on Exercise training increases size of hippocampus and improves memory.
- Bradley Hyman on Seeing Is Believing—Plaque Growth Is Slow, Tapers With Age
- Brian O’Nuallain on Conformational conversion during amyloid formation at atomic resolution.
- Wai-Tong Chien on Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study.
- Mathias Jucker on Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
- Daryl Bosco on Decreased stability and increased formation of soluble aggregates by immature superoxide dismutase do not account for disease severity in ALS.
- Terrence Town on CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.
- Donna M. Wilcock on CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.
- Brad Friedman on TDP-43 Turns Itself Off, Inclusions a False Lead
- Takaomi Saido on What was lost in translation in the DHA trial is whom you should intend to treat.